Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Anxiety

Treatments: Drug: (11C) flumazenil; Drug: AZD6280

Study type: Interventional

Funder types: Industry

Identifiers

NCT00681746

EudractCT 2007-006683-29

D0850C00011

Details and patient eligibility

About

The study is carried out in order to determine the relationship between the dose of AZD6280 and the blood concentration of AZD6280, and to investigate to which extent AZD6280 binds to GABAA receptors

Enrollment: 8 estimated patients

Sex: Male

Ages: 20 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Body Mass Index (BMI) of 18-30 kg/m2 and weight of 60-100 kg
• Clinically normal physical findings, medical history and laboratory values.

Exclusion criteria

• Clinically significant illness or clinical relevant trauma within 2 weeks before the study start.
• History of clinically significant heart arrythmias or heart disease/problems.
• Previous participation in a PET study within the past 12 months. Suffer from claustrophobia and would be unable to undergo MRI (magnetic resonance imaging) or PET scanning.

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

1

Experimental group

Treatment:

Drug: (11C) flumazenil

Drug: AZD6280